Fermenta Biotech Q3 FY25 earnings call: Revenue & Margins

The presentation does not explicitly detail any specific capex, capacity expansion, new plant, or project amounts, status, or timelines. It mainly focuses on financial performance, operational highlights, geographical revenue mix, and business segments without mention of new capacity additions or capital expenditure plans. Key relevant points related to facilities or assets include: - Capital work-in-progress figures on balance sheet: INR 63 Mn (H1-FY25), INR 16 Mn (FY24), INR 419 Mn (FY23), indicating ongoing investments. - Transfer of leasehold land at Saykha, GIDC Gujarat completed with transfer value of INR 18.7 crore (post Q3-FY25). - No explicit mention of new plant commissioning, capacity enhancement, or specific capex projects or timelines. Summary: No detailed capex, capacity expansion, or new project description with amounts, status, or timelines is provided in this presentation.

The provided Fermenta Biotech Limited investor presentation does not explicitly report or mention any details related to order book, order inflow, or pending orders. The presentation focuses on the following aspects instead: - Financial performance (standalone and consolidated) including revenue, EBITDA, PAT, margins, and EPS. - Segmental revenue details and geographical revenue mix. - Operational highlights, including volume growth in Human and Animal Nutrition. - Debt status and repayment of real estate debt.